You just read:

Stempeutics Receives Orphan Drug Designation (ODD) in the European Union for its Novel Stem Cell Drug "Stempeucel®" for the Treatment of Thromboangiitis Obliterans

News provided by

Stempeutics Research Pvt Ltd

01 Jun, 2015, 09:00 BST